Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

A recent study published in JAMA Psychiatry has uncovered promising evidence suggesting that glucagon-like peptide-1 (GLP-1) receptor agonists, particularly semaglutide and liraglutide, may be ...

Ozempic can cause bone density loss and I didn't think that would happen to me because I was only on it for a year. But I ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Finally, a few studies in mice have found that the medications can reduce the buildup of the protein tau in the brain, which is a key contributor to Alzheimer’s disease. Scaling back tau buildup could ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.